Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Active Pharmaceutical Ingredients Market

Active Pharmaceutical Ingredients Market Share

Report ID: GMI5415
Published Date: Jan 2023
Report Format: PDF

Download Free Sample

Active Pharmaceutical Ingredients Market Share

Pfizer Inc.
Merck & Co. Inc.
OfiChem Group
Biocon Ltd.
Divi's Laboratories Limited
Procyon Life Sciences
EUROAPI
Teva Pharmaceutical Industries Ltd.
Alivira Animal Health Ltd
Cipla Ltd.
Aurobindo pharma Ltd.
Dr. Reddys Laboratories Ltd.
Sun Pharmaceutical Industries Ltd.
Neuland Laboratories Ltd
Solara Active Pharma
Hikal Ltd.
SUANFARMA
Qilu Pharmaceutical Co. Ltd
NGL Fine-Chem Ltd
Aarti Drugs Ltd.

are some of the key participants in the active pharmaceutical ingredients market.

These firms are focusing on strategic collaborations and R&D programs to remain ahead in the competitive landscape. For instance, in July 2022, Merck & Co. Inc., an American pharmaceutical company, announced a collaboration deal with Orion, to develop and commercialize ODM-208 active pharmaceutical ingredient and other drugs targeting cytochrome P450 11A1 (CYP11A1) globally. This strategic alliance helped the company in expanding its product portfolio and global presence.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for active pharmaceutical ingredients recorded over USD 228.5 billion valuation in 2022 and is set to progress at more than 6.5% CAGR from 2023 to 2032 owing to rising drug R&D initiatives by public and private players.

Human segment is anticipated to cross USD 381 billion in revenue by 2032 end, due to the rising number of pharmaceutical R&D initiatives and innovation of cutting-edge medications with important clinical advantages.

Prescription segment is poised to expand at over 7% CAGR between 2023 and 2032 as a result of growing demand for medications for chronic diseases such as oncology, diabetes, cardiovascular diseases among others.

Europe APIs market is slated to reach over USD 119.5 billion by 2032 on account of the evolution of personalized medications, development of new high-tech therapies, and inventive delivery systems in the region.